two sub-clinical phases of HBV-ACLF (ACLF-M with 2>INR≥1.5, and ACLF-S with INR≥2) were included for high-throughput comparative proteomic analyses (Table  S1) .
Four parallel comparative proteomics experiments that employed triplex-2MEGA labeling and 2D-RPLC prefractionation coupled with high-throughput MS/MS experiment to compare protein abundances within each group. Two parallel shotgun proteomic experiments were performed to compare low abundant proteins (LAP) from all 5 groups. In the first experiment, LAP peptides from pooled CHB-M (n=10) and CHB-S (n=6) samples were tagged by medium and heavy dimethyl label, respectively, using a 3-plex N-terminal dimethylation after lysine guanidination (2MEGA) protocol described later. In the second experiment, LAP peptides from ACLF-M (n=9) and ACLF-S (n=10) samples were tagged by medium and heavy dimethyl label, respectively. The control samples (n=10) were pooled and tagged by light dimethyl label and used as a common reference in both experiments. Analogously, another two parallel shotgun proteomic experiments were performed to compare high abundant proteins (HAP) from 5 groups with the identical labeling scheme. The overall design of all four 3-plex 2MEGA-2DLC-MS/MS experiments was illustrated in Figure S1 .
Plasma samples from patients within the same group were pooled before proteomic analysis. The pooled plasma was divided into high and low abundant protein fractions by combinatorial peptide ligands library (CPLL) method with a modified protocol described previously [1] . Briefly, the ProteoMiner column (Catalog 163-3006, Bio-Rad, USA) was conditioned three times by 200 µL phosphate-buffered saline (PBS) supplemented with 0.1% sodium dodecyl sulfate (SDS). Before sample loading, 540 µL of pooled plasma was mixed with 60 µL PBS buffer, and SDS was added to a final concentration of 0.1%. The column was then loaded with 200 µL prepared plasma and incubated in room temperature (RT) with constant vortex for 1 h. After the loading, the column was centrifuged at 1,000 g for 2 min and then washed with 1 mL of PBS with 0.1% SDS and centrifuged for 2 min. Three loading-washing cycles were performed to load all 600 µL prepared plasma. The flow-through eluents from 3 loading cycles were combined and designated as high abundant protein (HAP) fraction. After removal of the residual wash buffer by 0.8 mL ddH 2 O, the CPLL bound proteins, i.e. low abundant proteins (LAP), were eluted with 1 mL of elution buffer (8 M urea, 2% SDS).
Both HAP and LAP proteins were subjected to digestion procedure modified from the FASP protocol described previously [2] . Briefly, proteins (~200 µg) were denatured and reduced with 25 mM dithiothreitol at RT for 30 min. The sample was centrifuged at 16,000 x g for 5 min. Sample was then applied to a 30 kDa MWCO spin filter (MRCPRT030, Millipore) and centrifuged. The sample was then wash by 200 µL 50 mM triethylammonium bicarbonate (TEAB). Protein alkylation was performed at dark with 30 mM iodoacetamide for 30 min in RT. After centrifugation, the sample was washed by 200 µL 50 mM TEAB twice. Trypsin (V5111, Promega) in 100 µL 50 mM TEAB was added in 1:50 enzyme to protein ratio. After 14 h digestion at 37°C, the tryptic peptides were collected in a new tube by centrifugation. All centrifugation steps in FASP protocol were carried out at 14,000 x g for 15 min.
Tryptic digests from different groups were then multiplexed by 2MEGA labeling protocol described previously [3] . Briefly, 100 µg (~1 µg/µL) peptides from each sample were adjusted to pH 11 by 2M NaOH. The amino group of lysine side chain was blocked via guanidination reaction at 37 °C for 1 h with 20 µL 6 M O-methylisourea. The pH was then adjusted to 5 with trifluoroacetic acid (TFA 
2DLC-MS/MS and data analysis.
The labeled peptides were then mixed according to the scheme in Figure S1 and further fractionated with high pH reverse phase chromatography on a 1260 HPLC System (Agilent) with an XBridge RP column (5 µm, 150 Å, 4.6*250 mm, Waters). Mobile phases A and B contain 2% and 98% acetonitrile (ACN), respectively, and were both adjusted to pH 10.0 using NH 4 OH. The solvent gradient was set as follows: 2-5% B in 2 min; 5-18% B in 11 min; 18-32% B in 9 min; 32-95% B in 1 min; maintained at 95% B for 5 min. The tryptic peptides were separated at a flow rate of 0.5 mL/min and monitored by UV at 214 nm. Concatenation pooling strategy [4] was used to generate a total of 20 and 4 fractions from LAP and HAP digest, respectively. The resolved peptides were dried by Speed Vac (Labconco) and reconstituted in 20 µl of 0.1% formic acid (FA), 2% ACN for subsequent LC-MS/MS analyses.
The peptides from each fraction were separated on an Acclaim PepMap RSLC nanoViper column (C18, 2 µm, 100 Å, 50 µm i.d. x 15 cm, Thermo Scientific) with a flow rate at 250 nL/min on an Easy nanoLC 1000 system (Thermo Scientific). The peptides were subsequently eluted with a five-step linear gradient (buffer A The overall data processing procedures for discovery proteomics study were illustrated in Figure S2 . For each 3-plex 2MEGA 2DLC-MS/MS experiment within the discovery comparative proteomic study, a consensus identification strategy with 2MEGA quantitation within the TransProteomic Pipeline environment (TPP, v.4.8) [5] was employed to process the data. Briefly, peak lists in mzXML format were generated from RAW files by ProteoWizard (v.3.0.5655) [6] for peak deisotope and charge state determination. Peak lists were then searched by Comet (2014.02 rev.2) [7] and MS-GF+ (beta.v10089) [8] in parallel against an Uniprot database contain both human and HBV proteins (downloaded at 2013.6, 88504 sequences) concatenated with reverse sequences as decoys. The search parameters were set to carboxyamidomethylation (+57.02) on cysteine, guanidination (+42.02) on lysine as fixed modifications, and oxidation (+15.99) on methionine as variable modification. To prepare search results for ASAPratio quantitation using isotopic 2MEGA triplet peak clusters, separate searches each using one isotopic dimethylation on peptide N-term (L+28.03 or M+32.06 or H+36.08) as fixed modification was performed. Other search parameters included one missed cleavage during trypsin digestion, a MS mass tolerance of 50 ppm, and MS/MS mass tolerance of 0.8 Da on monoisotopic mode.
For each separate search with different 2MEGA modification settings using either Comet or MS-GF+ algorism, all peptide-spectra matches (PSMs) from all fractions were compiled and filtered (probability>0.8) by PeptideProphet [9] using the non-parametric scoring model. Then results from both engines were combined by iProphet [10] to generate a consensus list of matched peptides. The combined peptide identifications were then subjected to two pair-wise (M vs. L, H vs. L) isotopic peak ratio calculations using the ASAPRatioPeptideParser [11] , with the following settings: use fixed scan range for light and heavy isotopic peaks; precursor m/z tolerance of 0.05 Da; only use static modification for quantitation. The resulting peptide lists with pair-wise 2MEGA ratio were assembled to give protein identification and quantitation by ProteinProphet in coupled with ASAPRatioProteinParser. For each protein, a p-value was calculated by ASAPRatioPvalueParser to estimate the probability of not changing as compared to the overall 2MEGA ratio distribution of all proteins according to the Lowess theorem [11] . The false discovery rate (FDR) was calculated by dividing the number of false hits by the number of all hits. Individual identification search results were compiled by ProteinProphet for pair-wise 2MEGA comparison.
Western Blot Analysis.
Liver tissue specimens were obtained from HBV-ACLF patients following total hepatectomy for subsequent liver transplantation. Liver biopsy specimens from healthy liver transplantation donor and CHB patients were used for comparison. The liver tissues were washed with ice-cold PBS. Proteins were extracted using RIPA lysis buffer containing protease inhibitor PMSF. Total protein was determined by BCA method (Thermo Scientific, USA). The proteins (20 µg) were separated on a 12% SDS-PAGE gel and then transferred to a polyvinylidene difluoride membrane (Millipore, USA). The membrane was blocked by 1% BSA in TBST and then incubated with primary antibodies at 4°C overnight. The primary antibodies used were rabbit polyclonal anti-HNF1α (#ab96777, 1:500 dilution, Abcam, USA), goat polyclonal anti-HNF4α (#sc-6557, 1:100 dilution, Santa Cruz, CA, USA) and rabbit monoclonal anti-β-actin (#4970, 1:1000 dilution, CST, USA). After washing, the membrane was then incubated with horseradish peroxidase conjugated secondary antibodies (#7074 anti-rabbit IgG, 1:2000 dilution, CST USA; #ab6741 anti-goat IgG, 1:2000 dilution, Abcam, USA) for 1h at RT. The membrane was visualized with enhanced ECL (Thermo Scientific, USA) following exposure to X-ray films. The software Image J (NIH, USA) was used to quantify the relative band intensity.
Selection of potential CHB and ACLF related biomarkers.
We used the following steps to select biomarker candidates for downstream validation (also summarized in Figure 2B ) : 1, Proteins with convincing evidence of presence, using the identification criteria detailed in previous section, in any one of the four 2MEGA-2DLC-MS/MS experiments were considered as detected, thus resulting a list of 255 HAP and 1087 LAP (Table S6 ) which were subjected to 2MEGA quantitative analyses.
2, Proteins shown expression differences (p-value < 0.05) at least in one comparison as determined by ASAPRatioPvalueParser were kept as DEP. Proteins with p-value of "N/A" or > 0.05 in all comparisons were discarded. For each protein deemed as differentially expressed, its original LC-MS1 isotopic peak pairs and chromatograms were manually inspected to filter out any mis-matches, interferences. After this step, 43 and 154 differentially expressed HAP and LAP (Table S6) were retained.
3, Potential markers found in HAP and LAP fractions were then combined. Proteins were kept as long as no contradictory quantitation were shown, e.g. proteins upregulated in HAP fraction but downregulated in LAP, or verse vice, in one pair-wise comparison were discarded. In addition, proteins that are highly expressed in liver according to the annotation on transcriptomic or proteomic level provided by www.genecards.org and http://www.proteinatlas.org were kept. After this step, 52 liver specific DEPs (Table S6) were retained.
4, Plasma samples were treated as described later in the "Targeted protein assay on an nLC-Orbitrap Q-Exactive MS" section to build peptide-spectra match library. After this step, 42 proteins with peptides successfully detected were kept as the final candidates for targeted proteomic validation (Table S7) .
5, The quantitative data from the targeted proteomic study were then filtered to remove proteins with missing value in more than 60% samples (~146 samples), thus resulted in a list of 28 quantified proteins (Table S8) .
Targeted proteomics.
To build the MS/MS spectra library for reference, a small set of samples (n=40) were first analyzed using LC-MSMS under the DDA scheme. Peptides (~500 ng) were reconstituted in phase A (2% ACN, 0.1% FA) and then enriched on a Symmetry C18 nanoACQUITY Trap Column (100 Å, 5µm, 180 µm x 20 mm). Peptide separation was carried out by a BEH C18 nanoACQUITY Column (130Å, 1.7 µm, 75 µm x 250 mm) on an nanoACQUITY UPLC system (Waters, Milford, MA) at a flow rate of 200 nL/min. The gradient started with 3% of mobile phase B (98% ACN, 0.1% FA) and increased to 8% in 4 min, then reached 18% B in 36 min and 32% B in 20 min. The gradient finally reached 90% B in 1 min and was then held for 14 min before it return to 3% B in 1 min and kept for 19 min re-equilibration until next injection. The total analysis time per injection was 95 min. The nanoLC was coupled to an Orbitrap Q-Exactive mass spectrometer (Thermo). The source was operated at 2.0 kV. The DDA analysis included a full MS survey scan from 400 to 1,200 Th at the resolution of 70,000 FWHM (at m/z 200) with automatic gain control (AGC) Th target set to 3e6, followed by 20 most intense peaks were selected for fragmentation by higher-energy collision dissociation (HCD). The MS/MS spectra were acquired with 17,500 FWHM resolution with AGC set to 2e5. Search results from MaxQuant against the human Uniprot database were loaded to Skyline (v3.5.0.9319) for selection of peptide ions according to the targeted proteomic workflow protocol described previously [12] .
A list of 222 peptides derived from 42 protein markers (Table S7 ) was generated for the targeted proteomic survey. Thereafter, all samples were analyzed using the same chromatographic conditions while the MS operated under the parallel-reaction monitoring (PRM) acquisition scheme, which included a full MS survey scan from 300 to 1,800 at the resolution of 17,500 FWHM (at m/z 200) with AGC set to 3e6, followed by HCD events to collect MS/MS spectra scheduled for a list of pre-defined 222 peptide targets. The isolation window was set to 2 Th. All MS/MS spectra were acquired at the resolution of 17,500 FWHM with AGC set to 1e6. The HCD normalized collision energy was set to 27%.
Data and materials availability
All mass spectrometric raw files are uploaded to iProX reservoir (http://www.iprox.cn/index, project ID: IPX0000769000) by this link: http://www.iprox.org/page/PSV023.html;?url=1533606841953rIHy, password: SoIJ. Figure S1 . Schematic diagram summarizing the workflow for comparative proteomics study at discovery stage.
Supplementary Figures
Samples were pooled within each groups and separated into low abundant (LAP) and high abundant (HAP) protein fractions. Totally 4 parallel 2MEGA-2DLC-MS/MS experiments were performed to compare: LAP from CHB-S, CHB-M and control; LAP from ACLF-S, ACLF-M and control; HAP from CHB-S, CHB-M and control; HAP from ACLF-S, ACLF-M and control. Figure S2 . Overall bioinformatics workflow to process proteomics data collected at discovery stage. A consensus identification strategy using two parallel search algorithms was used to process each 3-plex 2DLC-MS/MS dataset in 3 runs, each setting the H, M and L dimethylation, respectively, as fixed modification. The parallel search results were combined by iProphet while using ASAPRatio to calculate 2MEGA M/L or H/L ratio. ProteinProphet was used to generate the final protein level identification and quantitation results. Table S1 : Clinical characteristics of patients in the discovery proteomics study. The following tables are in separated Excel files: Table S6 : All plasma proteins quantified in the discovery comparative proteomic survey, including separate sheet of liver-specific differentially expressed proteins that shown high quantitation quality in 2MEGA data. 
Supplementary Tables
Controls (n=10) CHB-M (n=10) CHB-S (n=6) ACLF-M (n=9) ACLF-S(n=10)
